Grant: Alliance Grants
University of Victoria
$22,666.00
Manufacture of Active Pharmaceutical Ingredients using Transition Metal Catalysts for Selective Functionalization of C-H Bonds
EF 2022-23
Résumé
The manufacture of Active Pharmaceutical Ingredients (APIs), the medicinally-active compounds in pharmaceuticals, is one of the key areas that can affect the cost and availability of new medicines. Through a collaboration between the University of Victoria and GlaxoSmithKline, we propose to develop new, more efficient methods to synthesize and manufacture APIs. We aim to turn ubiquitous carbon-hydrogen bonds in precursor molecules into more complex molecular structures by creating a new class of chemical catalyst. These catalysts will be designed specifically to activate and break the required carbon-hydrogen bond, and then deliver the activated molecule to a second catalyst for elaboration. This dual catalyst approach will enable independent optimization of both halves of the synthesis: breaking the carbon-hydrogen bond and forming a new carbon-carbon bond.To realize this goal, we will use high-throughput experimentation to rapidly evaluate catalyst candidates and map the chemical reactivity space in a multivariate manner. Not only will this accelerate discovery of active catalysts, but also provide a path toward larger-scale implementation through chemical process understanding. By targeting several in-development APIs at GlaxoSmithKline, rather than simple model systems, we will also ensure that our new catalysts are suitable for complex molecule synthesis.Ultimately, this research aims to streamline manufacturing processes for new medicines, reduce the amount of chemical waste generated during this manufacture, and drive down the cost of new medicines under development.
Programme
Alliance Grants
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
557162-2020
Name nom
Leitch, David DC
Department département
Chemistry
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2020
Award amount
22666
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3704
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Synthetic methodology
Research subject fr
Méthodologie en synthèse
Installment
inst:3
Partie
1
Nb partie
3
Application title
Manufacture of Active Pharmaceutical Ingredients using Transition Metal Catalysts for Selective Functionalization of C-H Bonds
Application summary
The manufacture of Active Pharmaceutical Ingredients (APIs), the medicinally-active compounds in pharmaceuticals, is one of the key areas that can affect the cost and availability of new medicines. Through a collaboration between the University of Victoria and GlaxoSmithKline, we propose to develop new, more efficient methods to synthesize and manufacture APIs. We aim to turn ubiquitous carbon-hydrogen bonds in precursor molecules into more complex molecular structures by creating a new class of chemical catalyst. These catalysts will be designed specifically to activate and break the required carbon-hydrogen bond, and then deliver the activated molecule to a second catalyst for elaboration. This dual catalyst approach will enable independent optimization of both halves of the synthesis: breaking the carbon-hydrogen bond and forming a new carbon-carbon bond.To realize this goal, we will use high-throughput experimentation to rapidly evaluate catalyst candidates and map the chemical reactivity space in a multivariate manner. Not only will this accelerate discovery of active catalysts, but also provide a path toward larger-scale implementation through chemical process understanding. By targeting several in-development APIs at GlaxoSmithKline, rather than simple model systems, we will also ensure that our new catalysts are suitable for complex molecule synthesis.Ultimately, this research aims to streamline manufacturing processes for new medicines, reduce the amount of chemical waste generated during this manufacture, and drive down the cost of new medicines under development.